ciprofloxacin (Q3939) / Bayer, Novartis |
NCT01052298: Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) |
|
|
| Completed | 1 | 25 | Europe | Ciprofloxacin (Cipro inhale, BAYQ3939), Placebo | Bayer, Novartis | Disease, Pulmonary | 09/09 | 09/09 | | |
NCT00961038: Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) |
|
|
| Completed | 1 | 19 | Europe | Ciprofloxacin (PulmoSphere, BAYQ3939), Placebo | Bayer, Novartis Pharmaceuticals | Pulmonary Disease, Chronic Obstructive | 03/10 | 03/10 | | |
NCT01072942: To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III) |
|
|
| Completed | 1 | 16 | Japan | Ciprofloxacin (Cipro InhaIe, BAYQ3939), Placebo | Bayer | Pulmonary Disease, Chronic Obstructive | 06/10 | 07/10 | | |
NCT01168895: Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder |
|
|
| Completed | 1 | 12 | Europe | Cipro Inhale (Ciprofloxacin, BAYQ3939) | Bayer | Infection, Pulmonary Disease, Chronic Obstructive | 09/10 | 09/10 | | |
NCT00910351: Cipro Inhaler for Cystic Fibrosis Children Ages 6-12 |
|
|
| Completed | 1 | 19 | US | Ciprofloxacin (Cipro, BAYQ3939) | Bayer | Pseudomonas Infection | 10/10 | 10/10 | | |
NCT01538667: Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases |
|
|
| Completed | 1 | 24 | Europe | Ciprofloxacin (Cipro Inhale, BAYQ3939) | Bayer | Respiratory System | 07/12 | 07/12 | | |